# A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

> **NCT00217594** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 40 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Alemtuzumab (Campath)

## Key facts

- **NCT ID:** NCT00217594
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07-21
- **Primary completion:** 2017-02-06
- **Final completion:** 2017-02-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217594, "A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00217594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*